The Pharmacy Times® Cervical Cancer Resource Center is a comprehensive resource for clinical news and expert insights for the type of cancer that occurs in the cells of the cervix.
July 4th 2024
Antibody-drug conjugates (ADCs) revolutionize cancer therapy by delivering powerful drugs directly to tumors and minimize damage to healthy cells.
Focus on Human Papillomavirus Virus Vaccination in Adults and Young Adults
September 18th 2023Combining strong evidence-based recommendations with caring, compassionate, and frequent counseling opportunities hopefully will increase vaccine acceptance and ultimately reduce the incidence of HPV and associated cancers among our patients.
Read More
Predictive Model for Cervical Cancer Improved With Inclusion of Human Papillomavirus Genotypes
August 9th 2023Adding human papillomavirus genotypes to the predictive model had a significantly higher effect in improving accuracy compared to adding epidemiological factors and pelvic examination.
Read More
FDA Approves Bevacizumab Biosimilar for Six Types of Cancer
September 28th 2022Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
Roche’s CINtec PLUS Cytology Test Beneficial for Women at Higher Risk of Developing Cervical Cancer
November 16th 2021In the IMPACT trial, women who were positive for high-risk HPV received a follow-up triage test to help determine whether their cervical cells were transforming to cervical pre-cancer.
Read More